



Pain–Neuroinflammation Dyad: New Therapeutic Strategies or Pharmacological Targets to Counter Them

Guest Editors:

Dr. Giada Amodeo

Department of Pharmacological
and Biomolecular Sciences,
University of Milan, Via Vanvitelli
32, 20129 Milano, Italy

Dr. Silvia Franchi

Department of Pharmacological
and Biomolecular Sciences,
Università degli Studi di Milano,
Milano, Italy

Deadline for manuscript
submissions:

31 August 2024

Message from the Guest Editors

Dear Colleagues,

Chronic pain persistence can be traced back to a plethora of factors. Very often, the chronicization of pain does not derive from the initial damage progression but rather from central sensitization, where the neuroinflammatory condition plays a key role. Indeed, although the first studies had only focused on investigations at the neuron level, to date, the role of microglia and astrocytes, resulting in the production of cytokines, chemokines, neuropeptides, reactive oxygen species, second messengers, etc., has been slowly uncovered. Despite this, effective treatments, free of side effects, capable of blocking the pain and therefore of interrupting the vicious circle that is established, are currently not yet available. For these reasons, the identification of new targets or therapeutic strategies appears to be of great interest.

This Special Issue will mainly focus on the study of pain, neuroinflammation and related comorbidities, with a particular focus on finding solutions to prevent/slow down/suppress pain, neuroinflammation and related comorbidities. Both original articles and reviews will be considered for inclusion.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)